of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications ...

Gamifant (emapalumab-Izsg) selectively neutralizes interferon gamma, a key driver of hyperinflammation, and if approved, may also help reduce the need for high-dose glucocorticoids in these patients.” ...

The standard treatment for cutaneous lupus erythematosus is using immunosuppressants and biologic drugs to reduce inflammation ... including interferon-driven gene expression, in the lesions.

After 1 month of pegylated interferon therapy ... PCR tests were consistently negative and the patient tolerated the drug well with no adverse events. The dose of erythropoietin was increased ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and ...